drugset / Trial / NCT07281157
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, single-arm study evaluating the combination regimen of liposomal irinotecan, capecitabine, and enlonstobart combined with short-course radiotherapy as neoadjuvant therapy for locally advanced rectal cancer.
Timeline
- Start
- 2025-11-01
- Primary completion
- 2027-04-30
- Completion
- 2032-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | — |
| Subject | Enlonstobart | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |